With the business potentially at an important milestone, we thought we'd take a closer look at Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) future prospects. Citius Pharmaceuticals, Inc., a ...

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Petco Health & Wellness Co Inc (Symbol: WOOF), where a total of 26,358 contracts have ...

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) shares jumped 22.12% in after-hours trading to $1.27 on Tuesday, following the company’s fiscal year 2025 business update and the commercial launch of its ...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than ...

Citius Pharmaceuticals, Inc. CTXR announced that it has acquired the exclusive in-license rights of Dr. Reddy’s Laboratories RDY for E7777 (denileukin diftitox). The candidate is an improved ...

Citius Pharmaceuticals is a late-stage biotech with a drug to treat lymphoma, but their cash runway is not long enough for FDA approval. Their flagship drug, Lymphir, has shown promising results in a ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...